Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — ADA 2015 Investor & analyst event
31 slides from Novo Nordisk A/s Class B's conference presentation, Jun 7, 2015
Slide 1: ADA 2015 Investor & analyst event
Slide 1 ADA 2015 Investor & analyst event Boston, 7 June 2015 Mexico City – part of Cities Changing Diabetes
Slide 2: Forward-looking statements
ADA 2015 investor and analyst event Slide 2 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s Annual Report 2014 and Form 20-F, both filed with the SEC in February 2015, and w
Slide 3: Agenda
ADA 2015 investor and analyst event Slide 3 Agenda Time Topic Welcome – early insights from Saxenda® launch in the US 6.30 pm Jesper Brandgaard, CFO Liraglutide – new data for Saxenda® and Victoza® 6.35 pm Mads Krogsgaard Thomsen, CSO Faster-acting insulin aspart – controlling postprandial glucose 6
Slide 4: Majority of the anti-obesity medication is generic with new products driving market value expansion
ADA 2015 investor and analyst event Slide 4 Majority of the anti-obesity medication is generic with new products driving market value expansion 80% of AOM scripts are Recent launches increased Two latest oral AOM driving still generic total AOM market value branded market expansion TRx AOM branded A
Slide 5: Encouraging early script development for Saxenda
ADA 2015 investor and analyst event Slide 5 Encouraging early script development for Saxenda® AOM launch uptake Key launch observations TRx Naltrexone HCI & bupropion HCI Lorcaserin • Encouraging initial Saxenda® uptake volume Phentermine & topiramate Saxenda® 10,000 • Positive early feedback from p
Slide 6: Liraglutide – new data for Saxenda and Victoza
ADA 2015 investor and analyst event Slide 6 Liraglutide – new data for Saxenda® and Victoza® Mads Krogsgaard Thomsen EVP & Chief Science Officer
Slide 7: SCALE obesity and prediabetes: design of the largest clinical trial conducted within obesity
ADA 2015 investor and analyst event Slide 7 SCALE™ obesity and prediabetes: design of the largest clinical trial conducted within obesity Lifestyle intervention: -500 kcal/day hypo caloric diet + increased physical activity Re-randomisation: 1:1 Liraglutide 3 mg 3,731 people Liraglutide 3 mg Placebo
Slide 8: The majority of early Saxenda responders lost ≥5% or >10% weight and reversed prediabetes
ADA 2015 investor and analyst event Slide 8 The majority of early Saxenda® responders lost ≥5% or >10% weight and reversed prediabetes in SCALE™ trial Number of participants in different categories Reversal of prediabetes in early responders for Saxenda® and placebo after 56 weeks who completed 56 w
Slide 9: SCALE obesity and prediabetes: 3 years trial design
ADA 2015 investor and analyst event Slide 9 SCALE™ obesity and prediabetes: 3 years trial design Lifestyle intervention: -500 kcal/day hypo caloric diet + increased physical activity Re-randomisation: 1:1 Liraglutide 3 mg 3,731 people Liraglutide 3 mg Placebo Follow-up with: 2.4 mg 1.8 mg • BMI: ≥30
Slide 10: After three years of treatment Saxenda shows sustained weight loss and reduced risk of type 2 diabetes
ADA 2015 investor and analyst event Slide 10 After three years of treatment Saxenda® shows sustained weight loss and reduced risk of type 2 diabetes vs placebo in SCALE™ trial Sustained weight loss with Saxenda® SCALETM obesity and prediabetes trial Saxenda® effect on emerging type 2 diabetes Saxend
Slide 11: Saxenda treatment increases time to onset of type 2 diabetes vs placebo
ADA 2015 investor and analyst event Slide 11 Saxenda® treatment increases time to onset of type 2 diabetes vs placebo in 3-years SCALETM trial – For each 14 patients treated with Saxenda® for three years one case of diabetes is prevented Time to onset of T2D up to 160 weeks of treatment estimated su
Slide 12: Practicing Muslims with type 2 diabetes could benefit from GLP-1 during Ramadan
ADA 2015 investor and analyst event Slide 12 Practicing muslims with type 2 diabetes could benefit from GLP-1 during Ramadan but limited clinical data has existed Around 100 million Muslims estimated to have type 2 diabetes ADA recommendations during Ramadan • Metformin can be used safely Global pop
Slide 13: Randomised clinical trial investigating Victoza to improve glycaemic control during Ramadan
ADA 2015 investor and analyst event Slide 13 Randomised clinical trial investigating ability of Victoza® to improve glycaemic control during Ramadan Trial design Key trial results Overall results: • Victoza® was associated with a significantly larger reduction 341 people Victoza® + metformin in HbA1
Slide 14: Faster-acting insulin aspart – controlling postprandial glucose
ADA 2015 investor and analyst event Slide 14 Faster-acting insulin aspart – controlling postprandial glucose Peter Kurtzhals SVP Global Research
Slide 15: Unmet medical need for a faster-acting insulin approaching physiological insulin profile
ADA 2015 investor and analyst event Slide 15 Unmet medical need for a faster-acting insulin approaching physiological insulin profile and with better pump profile The aim of insulin therapy is to recreate normal Faster-acting insulin approaching physiological blood insulin profile insulin profile ev
Slide 16: In diabetes, PPG depends on early insulin appearance and action on the liver and peripheral tissues
ADA 2015 investor and analyst event Slide 16 In diabetes, PPG depends on early insulin appearance and action on the liver and peripheral tissues after a meal Elements influencing postprandial glucose (PPG) Early insulin appearance Action on the liver Peripheral tissues after a meal Proc Proc Add ess
Slide 17: Need for a faster-acting insulin to reduce hepatic glucose production around meal
ADA 2015 investor and analyst event Slide 17 Need for a faster-acting insulin to reduce hepatic glucose production around meal Hepatic glucose release drives overall higher Hepatic glucose production accounts for larger PPG release in T2D patients part of PPG in T2D vs healthy people PPG release Mea
Slide 18: Faster-acting insulin aspart shows higher glucose reduction in phase 1 trial
ADA 2015 investor and analyst event Slide 18 Faster-acting insulin aspart shows higher glucose reduction in phase 1 trial Faster-acting insulin aspart shows higher Greater glucose-lowering after meal with plasma glucose reduction in meal test faster-acting insulin aspart Faster-acting insulin aspart
Slide 19: Faster-acting insulin aspart shows additional improvement of HbA1c vs NovoRapid in phase 3 trial onset 1
ADA 2015 investor and analyst event Slide 19 Faster-acting insulin aspart shows additional improvement of HbA1c vs NovoRapid® in phase 3 trial onset® 1 onset® 1 trial design Headline results • Greater improvement of HbA1c with mealtime faster-acting Faster-acting insulin aspart (MT) insulin aspart c
Slide 20: Faster-acting insulin aspart shows larger improvement in 1-hour postprandial glucose in onset 2
ADA 2015 investor and analyst event Slide 20 Faster-acting insulin aspart shows larger improvement in 1-hour postprandial glucose vs NovoRapid® in phase 3 trial onset® 2 trial design Headline results • Similar reduction of HbA1c in both treatment groups Faster-acting insulin aspart (MT) • Statistica
Slide 21: IDegLira – superior HbA1c reduction compared to insulin glargine
ADA 2015 investor and analyst event Slide 21 IDegLira – superior HbA1c reduction with IDegLira compared to insulin glargine Peter Kristensen SVP Global Development
Slide 22: Remaining IDegLira phase 3 data shown at this year's ADA
ADA 2015 investor and analyst event Slide 22 Remaining IDegLira phase 3 data shown at this year’s ADA Data 2011 2012 2013 2014 presentation DUAL™ I: IDegLira vs individual 26-week Oral: components, 26 weeks, n=1,660 extension ADA 2014 DUAL™ II: IDegLira vs Oral: IDeg, n=400 ADA 2014 DUAL™ III: Switc
Slide 23: DUAL V phase 3 trial investigating IDegLira vs insulin glargine in type 2 diabetes
ADA 2015 investor and analyst event Slide 23 DUAL™ V phase 3 trial investigating IDegLira vs insulin glargine in people with type 2 diabetes Trial design Baseline characteristics IDegLira IGlar 557 people IDegLira + metformin with type 2 Mean age (years) 58.4 59.1 diabetes1 Mean diabetes duration 11
Slide 24: IDegLira associated with superior HbA1c reduction compared with insulin glargine in DUAL V
ADA 2015 investor and analyst event Slide 24 IDegLira associated with superior HbA1c reduction compared with insulin glargine in DUAL™ V Statistically significantly higher reduction of Both patient groups achieved similar FBG HbA1c with IDegLira vs IGlar at the end of trial HbA1c (%) IDegLira IGlar
Slide 25: Patients treated with IDegLira in DUAL V require lower insulin dose and achieve weight loss
ADA 2015 investor and analyst event Slide 25 Patients treated with IDegLira in DUAL™ V require lower insulin dose and achieve weight loss vs insulin glargine Statistically significantly fewer insulin units Statistically significant mean weight difference used by patients treated with IDegLira vs IGl
Slide 26: IDegLira associated with lower rates of confirmed and nocturnal hypoglycaemia in DUAL V
ADA 2015 investor and analyst event Slide 26 IDegLira associated with lower rates of confirmed and nocturnal hypoglycaemia vs insulin glargine in DUAL™ V Statistically significantly lower rate of Statistically significantly lower rate of confirmed confirmed hypoglycaemia with IDegLira vs IGlar noctu
Slide 27: More patients treated with IDegLira achieve treatment targets vs insulin glargine in DUAL V
ADA 2015 investor and analyst event Slide 27 More patients treated with IDegLira achieve treatment targets vs insulin glargine in DUAL™ V Few patients experience nausea when Proportion of subjects achieving HbA1c <7% treated with IDegLira and composite endpoints with IDegLira vs IGlar Frequency (%)
Slide 28: Concluding remarks
ADA 2015 investor and analyst event Slide 28 Concluding remarks Encouraging initial uptake of Saxenda® in the US but formulary access remains the key challenge 3-year treatment with Saxenda® reduces risk of type 2 diabetes by 80% compared with placebo in SCALE ™ trial Victoza® has the ability to imp
Slide 29: Speakers
ADA 2015 investor and analyst event Slide 29 Jesper Brandgaard, EVP & CFO Mads Krogsgaard Thomsen, EVP & CSO Peter Kurtzhals, SVP Global Research Peter Kristensen, SVP Global Development
Slide 30: Investor contact information
ADA 2015 investor and analyst event Slide 30 Investor contact information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the stock exchange in Novo Nordisk A/S Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on Investor Relations the New York Stock Exch
Slide 31: Appendix – Glossary
ADA 2015 investor and analyst event Slide 31 Appendix – Glossary Abbreviation Meaning Abbreviation Meaning Abbreviation Meaning ADA American Diabetes Association FAS Fasting plasma glucose LOCF Last observation carried forward ANCOVA Analysis of covariance GIR Glucose infusion rate PG Plasma glucose